Discover the
future
of biotech.
Discover the
future
of biotech.
Early-stage biotech is elusive by nature.
Most new companies are too small for major publications to cover, difficult for databases to track, and too numerous for any one person to follow.
Then, by the time the rest of the industry notices something interesting, the edge is gone.
That's why we built this...
The Biotech Voyager is the discovery layer for the early-stage ecosystem that, until now, couldn’t exist.
Why “couldn’t exist”? Because reliably uncovering early-stage biotech, and separating what’s valuable from what isn’t, requires serious technology.
The incentives to build that technology were never there…that is, until very recently.
So, what are we?
On the surface, we look like a news outlet. We’re not.
Under the hood sits a proprietary intelligence platform tracking 10,000+ companies and 15,000+ pipeline assets across biotech… every funding round, every pipeline move, every signal that matters.
We monitor the news landscape continuously, then score and rank every signal for its relevance to the early-stage ecosystem with algorithms first, human analysts second.
The analyses that matter (about the stuff that is too early or “inconsequential” for Fierce or Endpoints) become the stuff you read here.
So, what are we?
On the surface, we look like a news outlet. We’re not.
Under the hood sits a proprietary intelligence platform tracking 10,000+ companies and 15,000+ pipeline assets across biotech… every funding round, every pipeline move, every signal that matters.
We monitor the news landscape continuously, then score and rank every signal for its relevance to the early-stage ecosystem with algorithms first, human analysts second.
The analyses that matter (about the stuff that is too early or “inconsequential” for Fierce or Endpoints) become the stuff you read here.
